Evidence map›Paper›PMID 38962551›Full record

ArticleCancer diagnosis & prognosis

The Combination of Methionine Restriction and Docetaxel Synergistically Arrests Androgen-independent Prostate Cancer But Not Normal Cells.

Kohei Mizuta, Ryosuke Mori, Qinghong Han, Sei Morinaga, Motokazu Sato, Byung Mo Kang, Michael Bouvet, Yasunori Tome, Kotaro Nishida, Robert M Hoffman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kohei MizutaAntiCancer Inc., San Diego, CA, U.S.A.
Ryosuke MoriAntiCancer Inc., San Diego, CA, U.S.A.
Qinghong HanAntiCancer Inc., San Diego, CA, U.S.A.
Sei MorinagaAntiCancer Inc., San Diego, CA, U.S.A.
Motokazu SatoAntiCancer Inc., San Diego, CA, U.S.A.
Byung Mo KangAntiCancer Inc., San Diego, CA, U.S.A.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, U.S.A.
Yasunori TomeDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Kotaro NishidaDepartment of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Androgen-independent prostate cancer (AIPC) is resistant to androgen-depletion therapy and is a recalcitrant disease. Docetaxel is the first-line treatment for AIPC, but has limited efficacy and severe side-effects. All cancers are methionine-addicted, which is termed the Hoffman effect. Recombinant methioninase (rMETase) targets methionine addiction. The purpose of the present study was to determine if the combination of docetaxel and rMETase is effective for AIPC. Materials and Methods: The half-maximal inhibitory concentrations (IC Results: The IC Conclusion: The combination of a relatively low concentration of docetaxel and rMETase was synergistic and effective for AIPC. The present results also suggest that the effective concentration of docetaxel can be reduced by using rMETase, which may reduce toxicity. The present results also suggest the future clinical potential of the combination of docetaxel and rMETase for AIPC.

Indexed as

AIPCAndrogen-independent prostate cancercombination therapydocetaxelHoffman effectHs27methionine addictionmethionine restrictionnormal fibroblastsPC-3recombinant methioninaserMETasesynergy

Identifiers

PMID38962551
PMCPMC11215443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.